Archive 1995–2023

In 94 patients included to the Polish group of the EUFEST Study (European First Episode Trial), following drugs have been randomely used: haloperidol (27), olanzapine (26), amisulpride (26), quetiapin (12) and ziprazidon (3). Alike the whole EUFEST study group, Polish patients showed no differences in the severity of psychopathological symptoms after one year of antipsychotic treatment between the patients treated with haloperidol and patients treated with atypical antipsychotic agents. After one year of treatment, the level of negative symptoms was signifi cantly higher in patients treated with haloperidol. No signifi cant differences in the severity of psychopathological symptoms were observed between patients treated with atypical agents.